BioInvent International AB (STO:BINV) announced on Tuesday the signing of a manufacturing agreement with an undisclosed US cell therapy company for the production of cGMP compliant material to support their clinical development programmes.
This manufacturing agreement is expected to generate revenues of approximately USD1.5m, mainly in 2019.
BioInvent International is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development